PERFORMANCE IN INITIATING CLINICAL RESEARCH (Q3, 2013/14)

Research Ethics Committee Reference Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Benchmark Met?	Reason for not meeting benchmark
13/LO/0696	Glycaemic index testing of carbohydrate containing foods using a standardised method	23/05/2013	28/05/2013	Yes	Benchmark met
13/LO/0552	SinuSys Patency of Maxillary Sinus Ostia Study	05/06/2013	12/06/2013	Yes	Benchmark met
13/EE/0257	A Phase II Clinical Trial to Study the Efficacy and Safety of a combination regimen of MK-5172 and MK-8742 with Ribavirin (RBV) in Subjects with Chronic Hepatitis C Genotype 2 Infection	22/10/2013	29/10/2013	Yes	Benchmark met
12/NW/0711	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease	06/06/2013	17/06/2013	Yes	Benchmark met
13/LO/0126	Proportion of excision volume and length after treatment for cervical intra-epithelial lesions: cervical healing, quality of regenerated tissue, immunology and pregnancy outcome.	23/04/2013	07/05/2013	Yes	Benchmark met
12/LO/1156	A Phase III , Randomised, Double-blind , Controlled Study of Cabozantinib (XL184) vs Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100 -COMET EXELIXIS Study ? COMMET -1	06/02/2013	21/02/2013	Yes	Benchmark met
13/LO/0425	A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)and BT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1a Chronic Hepatitis C Virus (HCV) Infection (PEARL-IV)	18/04/2013	03/05/2013	Yes	Benchmark met
13/SC/0360	A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa 2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepatitis C who are Treatment-Naive or Relapsed on Treatment with Peginterferon Alfa-2a and Ribavirin	29/08/2013	16/09/2013	Yes	Benchmark met
13/LO/0830	Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment na?ve genotypes 1, 2, 3 or 4 in subjects co-infected with HIV	30/10/2013	19/11/2013	Yes	Benchmark met
13/LO/0006	A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects	09/04/2013	30/04/2013	Yes	Benchmark met
13/LO/0063	The acute effects of dietry components on central blood pressure	18/02/2013	12/03/2013	Yes	Benchmark met
12/LO/1278	Mechanisms of interplay between allergy and viruses in asthma: A human model of rhinovirus induced acute asthma exacerbations	23/01/2013	18/02/2013	Yes	Benchmark met
13/LO/1150	The role of left atrial ganglionated plexi sites that trigger pulmonary vein ectopy in the pathogenesis of paroxsymal atrial fibrillation	06/11/2013	02/12/2013	Yes	Benchmark met
13/LO/0223	A combined retrospective and prospective post marketing surveillance study in patients using Temperature controlled Laminar Airflow (TLA) - Protexo Registry	25/04/2013	23/05/2013	Yes	Benchmark met
12/LO/1289	Pre-exposure Option for reducing HIV in the UK: an open-label randomisation to immediate or Deferred daily Truvada for HIV negative gay men	12/02/2013	14/03/2013	Yes	Benchmark met
13/LO/0849	Clinical Assessment of a Novel Microprobe Array Continuous Glucose Monitor for Type 1 Diabetes	23/10/2013	22/11/2013	Yes	Benchmark met
12/LO/1570	Neuroinflammation in HIV individuals stable on cART: a [11C] PBR28 PET CT study	25/02/2013	28/03/2013	Yes	Benchmark met
11/LO/1023	A 12Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Ozurdex Versus Lucentis in Patients with Branch Retinal Vein Occlusion	03/06/2013	04/07/2013	Yes	Benchmark met
11/SS/0092	Trial of BIBW 2992 in suspected mutant EGFR lung cancer patients unfit for chemotherapy	11/09/2013	15/10/2013	Yes	Benchmark met

13/LO/0206	A phase 3 evaluation of Daclatasvir in combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chroinic Hepatitis C Genotype 1b who are Treatment Na?ve or Prior Replasers to Alfa/RBV Therapy	08/07/2013	12/08/2013	Yes	Benchmark met
10/H0706/65	A phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer	15/02/2013	25/03/2013	Yes	Benchmark met
12/EE/0499	A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly with Peginterferon alfa-2b and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Virus Infection	10/01/2013	18/02/2013	Yes	Benchmark met
12/LO/0894	The role of 123I SPECT-CT scintigraphy as a novel diagnostic test in patients with liver tumours	02/05/2013	10/06/2013	Yes	Benchmark met
13/SC/0146	A phase III, randomised, open label, activecontrolled study of an interferon free regimen of BI 207127 in combination with Faldaprevir and Ribavirin compared to Telaprevir in combination with pegylated interferona and ribavirin in treatmentnaïve patients with chronic genotype 1b Hepatitis C Virus infection	03/05/2013	14/06/2013	Yes	Benchmark met
13/EE/0276	A Phase 3B Randomized, OpenLabel MultiCenter Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection	17/09/2013	31/10/2013	Yes	Benchmark met
13/LO/0455	Retinal Embolisation in Transcatheter Aortic Valve Implantation: Pilot Study	17/05/2013	02/07/2013	Yes	Benchmark met
13/LO/0487	The effectivness and acceptability of a computerised self-help guide for women with vaginismus	09/05/2013	25/06/2013	Yes	Benchmark met
13/LO/1121	A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First Line Treatment in Metastatic Non Small Cell Lung Cancer Patients with Activating EGFR Mutations Who Have Disease Control after an 8 Week Lead In Treatment with Erlotinib	11/12/2013	41668	Yes	Benchmark met
13/LO/1352	A phase II, open-label, multi-centre, randomised study to investigate the efficacy and safety of MPDL3280A (anti-PD-L1 antibody) compared with docetaxel in patients with non-small cell lung cancer after platinum failure	23/10/2013	41624	Yes	Benchmark met
11/SW/0036	Randomised Controlled Trial of the Efficacy and Mechanism of Levothyroxine Treatment on Pregnancy and Neonatal Outcomes in Women with Thyroid Antibodies	07/01/2013	05/03/2013	Yes	Benchmark met
13/WM/0231	Safety of Nasal Influenza Immunisation in Egg Allergic Children The SNIFFLE study	20/08/2013	17/10/2013	Yes	Benchmark met
12/WM/0341	A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular events When AMG 145 is Used in Combination With StatinTherapy in Patients with Clinically Evident Cardiovascular Disease	03/07/2013	04/09/2013	Yes	Benchmark met
13/LO/0615	A Randomized, Controlled, Open-Label, Phase 2, Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer	29/08/2013	31/10/2013	Yes	Benchmark met
13/LO/1305	Systematic Assessment of Pulmonary Artery Haedodynamics using Wave Intensity Analysis	10/10/2013	12/12/2013	Yes	Benchmark met
12/WS/0184	Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal AntibodyKW-0761 or Investigators Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)	29/04/2013	02/07/2013	Yes	Benchmark met
13/NW/0171	A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT-301 (Levodopa Inhalation Powder) in Parkinson?s Disease Patients With Motor Response Fluctuations (OFF Phenomena)	13/05/2013	19/07/2013	Yes	Benchmark met
12/NW/0682	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia	13/03/2013	20/05/2013	Yes	Benchmark met
12/LO/1748	A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed Dose Combination + Ribavirin for 12 and 24 weeks in Treatment-Na?ve Subjects with Chroinc Genotype 1 HCV Infection	25/01/2013	04/04/2013	Yes	Benchmark met
12/LO/1343	A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating CNTO 3157 in Healthy Normal and Asthmatic Subjects Inoculated with Human Rhinovirus Type 16	21/05/2013	01/08/2013	No	Delayed 'Green Light'. Complex volunteer study.
11/WS/0039	A Phase I/IIa trial of AZD4547 in combination with Cisplatin and Capecitabine (CX)	08/08/2013	23/10/2013	No	Multiple amendments following submission of VRA

12/LO/1598	A randomized, open label study to evaluate the safety and efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 (coadministered with Ribavirin (RBV) in adults with genotype 1 chronic hepatitis C virus (HCV) infection and cirrhosis (TURQUOISE II)	12/11/2012	28/01/2013	No	NHS permissions and/or contract negotiation
12/EE/0176	Randomised, phase IV, placebo-controlled, comparative study to evaluate the efficacy and safety of tapering methotrexate (mtx) dosage versus maintaining the dosage in patients with severe active rheumatoid arthritis (ra) who have demonstrated an inadequate response to prior disease-modifying anti-rheumatic drugs (dmards) treatment and have initiated roactemra? (tocilizumab, tcz) in combination with mtx	12/12/2012	28/02/2013	No	Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
13/WM/0027	Venous Insufficiency and Neuromuscular Stimulation	15/04/2013	04/07/2013	No	Staff availability / recruitment delay
12/LO/1597	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 co-administered with Ribavirin (RBV) in treatment ?experienced adults with genotype 1 chronic hepatitis C virus (HCV) infection (SAPPHIRE-II)	13/11/2012	05/02/2013	No	NHS permissions and/or contract negotiation
11/LO/1598	Assessing Treatment Response of Peritoneal Metastases in Ovarian Cancer Using Diffusion Weighted Magnetic Resonance Imaging (DISCOVAR)	04/12/2012	27/02/2013	No	Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
13/SW/0124	A performance evaluation study of UROSENS(TM) MCM5-ELISA for the detection of prostate cancer in patients with known disease and in those presenting with raised serum prostate-specific antigen and/or abnormal prostate gland morphology	16/07/2013	09/10/2013	No	Eligible patients not yet identified &/or consented in clinics
13/LO/0541	Bedside screening for post-partum iron deficiency anaemia: An evaluation of the Hemacue 201 device for point of care testing to screen for post-partum anaemia	20/05/2013	14/08/2013	No	Staff availability / recruitment delay
12/LO/1176	STREAMLINE-C: Streamlining Staging of Colorectal Cancer with Whole Body MRI	22/03/2013	17/06/2013	No	NHS permissions and/or contract negotiation
13/LO/0115	A phase I clinical trial investigating immunisation strategies using DNA, MVA and rgp140 adjuvanted with GLAAF to maximise antibody responses	22/03/2013	19/06/2013	No	Delayed site initiation visit (SIV). NHS permissions and/or contract negotiation.
13/WA/0064	A performance evaluation study of UROSENS(TM) MCM5 ELISA test in the diagnosis of bladder cancer in patients presenting with haematuria and lower urinary tract symptoms with suspicion of malignancy	28/03/2013	02/07/2013	No	Delayed site initiation visit (SIV). First patient was recruited within 30 days of SIV. NHS permissions and/or contract negotiation.
13/SC/0348	A randomized, OpenLabel, Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib	22/08/2013	27/11/2013	No	Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
10/H0715/48	A Randomised Multicentre Accelerated Radiotherapy Study of Dose Escalated Intensity Modulated Radiotherapy vs Conventional Dose Intensity Modulated Radiotherapy in Patients Receiving Treatment for Locally Advanced Laryngeal and Hypopharyngeal Cancers	15/02/2013	28/05/2013	No	NHS permissions and/or contract negotiation
13/LO/0410	Preventing enduring behavioural problems in young children through early psychological intervention: A pilot study (Healthy Start Happy Start: Helping with Children's Behaviour)	07/06/2013	21/09/2013	No	Eligible patients not yet identified &/or consented in clinics
12/LO/1937	Brain muscle axis during treatment of hepatic encephalopathy with L-ornithine L-aspartate (A phase IV randomized, double-blind, placebo-controlled trial)	14/01/2013	02/05/2013	No	Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
12/LO/1361	A two-centre randomised controlled trial investigating the effect of remote ischaemic preconditioning (RIPC) on blood and myocardial biomarkers of stress and injury-related signalling in patients having isolated coronary artery bypass grafting (CABG) or aortic valve replacement (AVR) using cardiopulmonary bypass (CPB)	07/11/2012	25/02/2013	No	NHS permissions and/or contract negotiation
12/LO/1823	A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1 Infected, Antiretroviral Treatment-Naive Women	17/05/2013	10/09/2013	No	Eligible patients not yet identified &/or consented in clinics
12/LO/1211	A phase III, open-label, multi centre pilot study to assess the feasibility of switching, individuals receiving Atripla or Kivexa plus Efavarinz with continuing Central Nervous System (CNS) toxicity, to a fixed dose combination of tenofovir/emtricitabine/rilpivirine (Eviplera)	10/10/2012	04/02/2013	No	NHS permissions and/or contract negotiation
12/LO/1769	Exploring the Physiological role of proportionate in glucose homoeostasis in man.	15/01/2013	20/05/2013	No	Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

12/LO/1981	A Randomized, Multicenter, Open-Label Phase III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine Versus Trastuzumab As Adjuvant Therapy For Patients With Her2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically In The Breast Or Axillary Lymph Nodes Following Preoperative Therapy	02/05/2013	06/09/2013	No	Eligible patients not yet identified &/or consented in clinics
13/LO/0535	A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	23/05/2013	30/09/2013	No	Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
12/NW/0431	A Multi-center, open-label, adaptive, randomised study of Palifosfamide-tris, a novel DNA crosslinker, in combination with Carboplatin and Etoposide (PaCE) chemotherapy versus Carboplatin and Etoposide (CE) alone in chemotherapy naive patients with extensive stage Small Cell Lung Cancer	10/10/2012	26/02/2013	No	Study closed prematurely by sponsor.
11/EE/0256	Multi-centre, open label, prospective, consecutive series registry database of BioPoly RS Partial Resurfacing Knee implant	18/06/2013	12/11/2013	No	Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
12/SS/0007	A randomised Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastic Pancreatic Cancer Receiving Chemotherapy	10/12/2012	20/05/2013	No	Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
11/WS/0090	A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium.	08/03/2013	29/08/2013	No	Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
12/SC/0014	Vasopressin vs. Noradrenaline as Initial therapy in Septic Shock	13/08/2012	09/02/2013	No	Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
11/LO/1465	Diagnostic accuracy of MRI, diffusion-weighted MRI, FDG-PET/CT and FEC-PET/CT in the detection of lymph node metastases in surgically staged endometrial and cervical carcinoma	19/09/2012	19/03/2013	No	Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
12/SC/0540	A phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in combination with Faldaprevir and Ribavirin in Treatment-Na?ve Patients with Chronic Genoptype 1 HCV Infection	12/10/2012	19/04/2013	No	NHS permissions and/or contract negotiation
11/LO/1369	A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy	27/03/2013	02/10/2013	No	Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
12/WM/0087	Phase I/II Randomised Trial of 5-Azacitidine versus 5-Azacitidine in combination with Vorinostat in patients with Relapsed Acute Myeloid Leukaemic Ineligible for Intensive Chemotherapy (RAvVA).	26/02/2013	11/09/2013	No	Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
12/LO/0777	Maraviroc Switch Central Nervous System (CNS) Substudy: a substudy of MARCH, a randomised, open label study to evaluate the efficacy and safety of maraviroc (MVC) as a switch for either nucleoside or nucleotide analogue reverse transcriptase inhibitors (N (t) RTI) or boosted protease inhibitors (PI/r) in HIV -1 infected individuals with stable, well controlled plasma HIVRNA while taking their first N(t)RTI + PI/r regimen of combination antiretroviral therapy (cART)	12/02/2013	29/08/2013	No	Eligible patients not yet identified &/or consented in clinics
12/EE/0400	An open label study of GS-7977 + Ribavirin for 12 weeks in subjects with chronic HCV infection who participated in prior studies evaluating GS-7977	10/01/2013	13/08/2013	No	NHS permissions and/or contract negotiation
10/MRE00/12	Does Metformin reduce excess birthweight in offspring with a raised BMI (>30) women? A randomised controlled trial of efficacy, explorations of mechamisms and evaluation of other pregnancy complications	24/06/2012	31/01/2013	No	NHS permissions and/or contract negotiation
11/LO/0185	PROMIS Prostate MRI Imaging Study (MRC PR11) Evaluation of Multi-Parametric Magnetic Resonance Imaging in the Diagnosis and Characterisation of Prostate Cancer	01/04/2013	13/11/2013	No	Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
11/WM/0287	A randomized multicenter study to compare the efficacy of additional tumour debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer	10/10/2012	25/05/2013	No	Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
12/SC/0538	A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD)	28/11/2012	15/07/2013	No	Delayed site initiation visit (SIV). NHS permissions and/or contract negotiation.
12/LO/0261	Hellenic- Anglo Research into Morning or Night antihypertensive drug deliverY trial (HARMONY)	17/10/2012	22/07/2013	No	Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
09/H0722/76	A randomised phase III trial of single fraction radiotherapy compared to multifraction radiotherapy in patients with metastatic spinal cord compression	26/02/2013	30/12/2013	No	Eligible patients not yet identified &/or consented in clinics

12/LO/0486	An Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of PF-05280602. A Recombinant Factor Villa Variant (813), in adult Hemophilla A and B Subjects with or without inhibitors	21/11/2012	15/11/2013	No	Rare disease study. Major protocol amendment(s) submitted prior to recruitment. NHS permissions and/or contract negotiation.
11/NW/0782	A phase III randomised trial of adjuvant chemotherapy versus observation in transitional cell carcinoma of the upper tract	21/05/2012	11/07/2013	No	Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
12/WS/0180	A multicenter, two stage, phase II study, evaluating the efficacy of oral BEZ235 plus best supportive care (BSC) versus placebo plus BSC in the treatment of patients with advanced pancreatic neuroendocrine tumors (pNET) after failure of mTOR inhibitor therapy	05/10/2012			NHS permissions and/or contract negotiation
09/H0406/106	Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCL.	10/10/2012			NHS permissions and/or contract negotiation
11/NW/0075	Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal nodal N2 involvement	10/10/2012			Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
10/H0505/19	ACR/EULAR endorsed study to develop new classification and diagnostic criteria for primary systemic vasculitis	23/01/2013			Staff availability / recruitment delay
10/H1107/46	Non cirrhotic portal hypertension: An emerging clinically significant liver disease in patients with human immunodeficiency virus	04/02/2013			Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
12/LO/1896	Effect of Nike FuelBand on Exercise and Function in Claudicants	26/02/2013			Eligible patients not yet identified &/or consented in clinics
13/LO/0036	The effect of a low-carbohydrate, ketogenic diet verses a low-fat diet on weight loss and appetite regulation in type 2 diabetics	27/02/2013			Eligible patients not yet identified &/or consented in clinics
12/NW/0555	Randomized Phase II Study of BEZ235 vs. everolimus in Advanced Pancreatic Neuroendocrine Tumors	05/03/2013			Eligible patients not yet identified &/or consented in clinics
13/EE/0010	CUTHIVAC 001 safety and immunogenicity of an HIV vaccine; version 1	08/03/2013			Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
12/LO/1358	Randomized, Double-Blind, Phase 3 Study of TAS-102 Plus Best Supposrtive Care (BSC) Versus Placebo Plus BSC In Patients With Metastatic Colorectal Cancer Refractory To Standard Chemotherapies	11/03/2013			Eligible patients not yet identified &/or consented in clinics
12/NE/0342	A multicentre, randomised, double blind, placebo-controlled pivotal study to evaluate the efficacy and safety of GFT505 80mg and GFT505 160mg on steatohepatitis in patients with non-alcoholic steatohepatitis (NASH)	11/03/2013			Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
11/EM/0450	A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and ECOG Performance Status 2 (PaZ02)	02/04/2013			Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
09/H0801/96	A Phase I Study Of Everolimus Therapy Before Nephrectomy In Metastatic Renal Cell Cancer (E-PREDICT)	24/04/2013			Eligible patients not yet identified &/or consented in clinics
11/YH/0260	Randomised Phase II of FC+ofatumumab vs FC+ofatumumab (high dose) for patients with relapsed CLL who are eligible for fludarabine-based therapy (i.e. late relapses after FC or FCR or prior therapy with alkylators)	25/04/2013			Eligible patients not yet identified &/or consented in clinics
13/WM/0017	Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism	14/05/2013			NHS permissions and/or contract negotiation
NULL	Self-Management education for adults with poorly controlled epILEpsy(SMILE): A project involving a randomised controlled trial	21/05/2013			Eligible patients not yet identified &/or consented in clinics
11/LO/2047	Outcome measures in sleeve gastrectomy after staple line reinforcement: Seamguard vs Duet TRS	22/05/2013			Eligible patients not yet identified &/or consented in clinics
12/LO/1762	Left ventricular MultiSpot Pacing for CRT (iSpot)	22/05/2013			Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
12/NW/0802	A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod (0.6 mg/day or 1.2 mg/day) in subjects with relapsing remitting multiple sclerosis (RRMS)	04/06/2013			External contractor delays.
13/LO/0493	A randomised controlled trial of internet based cognitive behavioural therapy (CBT) versus treatment as usual (TAU) for pregnant women with symptoms of depression	10/06/2013			Staff availability / recruitment delay
12/LO/0720	A Phase 1 Randomised Study of MEDI-551 in Subjects with Relapsing-Remitting Multiple Sclerosis	24/06/2013			Multiple amendments following R&D approval.
13/YH/0117	Multi-Channel Near Infrared Spectroscopy to Detect Spreading Depolarisations in Brain Injured Patients	01/07/2013			Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation

12/LO/1133	A randomised phase 2 trial investigating the additional benefit of hydroxychloroquine (HCQ) to short course radiotherapy (SCRT) in patients aged 70 years and older with high grade gliomas (HGG)	23/07/2013			Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
13/SC/0174	A phase 2b dose-ranging, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against lysyl oxidase like moleculae 2 (LOXL2) in subjects with Primary Sclerosing Cholangitis (PSC)	24/07/2013			Eligible patients not yet identified &/or consented in clinics
13/LO/0097	A phase 2b dose-ranging, randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against Lysyl oxidase like molecular 2 (LOXL2) in subjects with advanced liver fibrosis but not cirrhosis secondary to non alcoholic steatohepatitis (NASH) GS-US-321-0105 - (GS-6624 for Advanced Liver Fibrosis)	24/07/2013			Eligible patients not yet identified &/or consented in clinics
13/SC/0249	A phase 2b dose-ranging, randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against Lysyl oxidase like molecular 2 (LOXL2) in subjects with compensated cirrhosis secondary to non alcoholic steatohepatitis (NASH) GS-US-321-0106 (cirrhosis due to NASH))	29/07/2013			Eligible patients not yet identified &/or consented in clinics
12/EM/0369	Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage TICH2	30/07/2013			NHS permissions and/or contract negotiation
12/LO/1188	A Study of HSP90 Inhibitor AT13387 Alone or in Combination with Abiraterone Acetate in the Treatment of CastrationResistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone	01/08/2013			Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
13/LO/0855	A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymphoma	02/08/2013			Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
12/LO/1636	Validation of Sensium wireless device in a paediatric population	07/08/2013			Eligible patients not yet identified &/or consented in clinics
13/SC/0311	A randomized, controlled, doubleblind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs. MabThera? plus cyclophosphamide, vincristine, prednisone, followed by GP2013 or MabThera maintenance therapy in patients with previously untreated, advanced stage follicular lymphoma	07/08/2013			NHS permissions and/or contract negotiation
13/WA/0178	A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (protocol ID EMR200592-001)	14/08/2013			Eligible patients not yet identified &/or consented in clinics
13/NE/0177	A phase II, randomised, double-blind, placebo-controlled study to evaluate LUM001, an apical sodium-dependent bile acid transporter inhibitor (ASBTi), in combination with ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis	18/08/2013			Eligible patients not yet identified &/or consented in clinics
13/LO/1279	To evaluate the role of LifeNote in rates of medicine adherence and also its acceptability in patients at high multifactorial risk of developing cardiovascular disease attending the MyACtion Westminster programmme	20/08/2013			Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
11/NE/0214	Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms	21/08/2013			Eligible patients not yet identified &/or consented in clinics
13/SC/0208	A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01B + ChAd63 and MVA encoding ME TRAP and also RTS,S/A01B alone	25/08/2013			Eligible patients not yet identified &/or consented in clinics
13/NE/0125	PRESTO Neo.1.C/E	29/08/2013			Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
13/LO/0501	A phase 2, randomised, dose-ranging study to assess the safety and anti-cytomegalovirus (CMV) activity of maribavir versus valganciclovir for treatment of CMV infections in transplant recipients who do not have CMV organ disease	06/09/2013			Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
13/EE/0199	An Exploratory Study of the Safety and Efficacy of BOTOX for the Treatment of Premature Ejaculation	11/09/2013			Eligible patients not yet identified &/or consented in clinics / NHS permissions and/or contract negotiation
13/NW/0265	A trial of de-escalation and stopping treatment in chronic myeloid leukaemia patients with excellent responses to tyrosine kinase inhibitor therapy (De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in chronic myeloid leukaemia)	18/09/2013			NHS permissions and/or contract negotiation
12/LO/1698	Valacyclovir in Delaying Antiretroviral Treatment Entry (VALIDATE)	24/09/2013			Eligible patients not yet identified &/or consented in clinics

13/LO/0129	A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects	25/09/2013			Eligible patients not yet identified &/or consented in clinics
13/LO/0699	Evaluating the effects of the novel GLP-1 analogue, liraglutide, in patients with Alzheimer's disease (ELAD Study).	01/10/2013			NHS permissions and/or contract negotiation
13/LO/0683	Predicting Delirium After Neck of Femur Fracture	02/10/2013			NHS permissions and/or contract negotiation
13/NW/0464	A PlaceboControlled, Multicenter, DoubleBlind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN6556 in Subjects with Acute on Chronic Liver Failure	03/10/2013			Eligible patients not yet identified &/or consented in clinics
13/SC/0383	A Two Part, Randomized Clinical Trial to Study Biomarkers of MK8237 (SCH 900237) Treatment in Subjects with House Dust Mite Induced Allergic Rhinitis or Rhinoconjunctivitis	22/10/2013			70-days from Date of VRA not exceeded by end of reporting period.
13/LO/1290	A Followup Study to Assess Resistance and Durability of Response to AbbVie DirectActing Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection	22/10/2013			70-days from Date of VRA not exceeded by end of reporting period.
13/WA/0328	Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer	31/10/2013			70-days from Date of VRA not exceeded by end of reporting period.
13/LO/1302	A Phase IIIb randomised, openlabel study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in HIV1 infected antiretroviral therapy naive women.	01/11/2013			70-days from Date of VRA not exceeded by end of reporting period.
13/SC/0368	Comparison of ultra low dose Oral versus Transdermal Hormone Therapy on coagulation activation and metabolic risk factors for Cardiovascular Disease	08/11/2013			70-days from Date of VRA not exceeded by end of reporting period.
13/SC/0291	An open label, phase 1 study to evaluate the impact of severe hepatic impairment on the pharmacokinetics and safety of vemurafenib in BRAFV600 mutation-positive cancer patients	18/11/2013			70-days from Date of VRA not exceeded by end of reporting period.
13/LO/1639	Patient matched osteotomy to correct angular deformities in knee arthrosis	02/12/2013			70-days from Date of VRA not exceeded by end of reporting period.